SLGL — Sol-Gel Technologies Ltd.

Nasdaq · Health Care · Pharmaceuticals · CIK 1684693 · Israel
Last close
$74.50
Market Cap
$241.77M
52W High
$97.97
52W Low
$61.92
ADV30
31,013
Next earnings
2026-05-28
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2025 696,000 -3,411,000 -2,987,000 29,917,000 11,033,000 7,106,000
Sep 2025 400,000 -6,288,000 -5,942,000 34,592,000 6,705,000 8,562,000
Jun 2025 17,261,000 11,230,000 11,610,000 39,307,000 10,221,000 7,425,000
Mar 2025 1,031,000 9,069,000 -8,808,000 27,063,000 16,890,000 6,891,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-237,010,000
Inventory
Receivables
$1,968,000
ST Investments
$12,966,000
EBIT TTM
$10,600,000
Pretax Income TTM
$-6,127,000
Interest Exp TTM
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$19,388,000
EBITDA
$-7,483,000
Free Cash Flow
$617,000
Enterprise Value
$186,327,984
Total Cash
$23,999,000
Total Debt
$991,000
Shares Out
3,245,270
Trailing EPS
$-2.19
Book Value
$8.19
ROE
-23.7%
ROA
-14.4%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 19,388,000 -7,538,000 -6,127,000 29,917,000 7,106,000 322,000
Dec 2024 11,538,000 -12,014,000 -10,580,000 35,846,000 6,996,000 -13,889,000
Dec 2023 1,554,000 -29,305,000 -27,238,000 45,287,000 6,643,000 -17,730,000
Dec 2022 3,883,000 -16,244,000 -14,923,000 46,628,000 4,415,000 -9,484,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-14.72

Peers — same industry

TickerNameMarket CapLastDaily %
CNTX Context Therapeutics Inc. $241.64M $2.63
NERV Minerva Neurosciences, Inc. $243.19M $5.22
ADAG Adagene Inc. $245.79M $3.72
WHWK Whitehawk Therapeutics, Inc. $235.89M $4.77
BCYC BICYCLE THERAPEUTICS PLC $230.21M $4.57

News headlines (Yahoo Finance, 1h cache)

US Equity Indexes Fall Amid Uncertainty Over US-Iran Truce Talks
2026-03-24 20:48 · Yahoo
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering
2026-03-24 01:38 · Yahoo
Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Misses Revenue Estimates
2026-03-19 18:00 · Yahoo
Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025
2026-03-19 12:53 · Yahoo
Sol-Gel Technologies (NASDAQ:SLGL) shareholders have earned a 940% return over the last year
2026-02-11 18:23 · Yahoo
We Think Sol-Gel Technologies (NASDAQ:SLGL) Can Easily Afford To Drive Business Growth
2025-12-29 12:41 · Yahoo
Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease
2025-12-17 12:00 · Yahoo
Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
2025-11-20 12:30 · Yahoo
Insiders At Sol-Gel Technologies See Good Returns After Buying Stock Worth US$867.1k
2025-11-10 13:28 · Yahoo
Sol-Gel Technologies (NASDAQ:SLGL) shareholders have earned a 240% return over the last year
2025-09-04 18:20 · Yahoo

Recent Insider Activity

FiledTradeInsiderTitleType PriceQtyValue
2026-05-22 16:05:21 2026-05-20 Opaleye Management Inc. 10% P - Purchase 64.43 1563 100712